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Introduction 
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the 
intestine, comprised primarily of two diseases: ulcerative colitis (UC) and Crohn’s 
disease (CD). The localization and pattern of disease are different. CD can 
typically affect any location throughout the entire gastrointestinal tract in a 
discontinuous manner, most commonly in the terminal ileum, with inflammation 
that is typically transmural and often granulomatous. Conversely, UC localizes to 
the rectum and colon in a confluent pattern and is limited to the mucosa and 
submucosa.  
Extra-intestinal manifestations of IBD 
IBD is frequently associated with extra-intestinal manifestations and autoimmune 
disorders. IBD-associated extra-intestinal manifestations can involve many organ 
systems, where they can follow the course and timing of the bowel inflammation 
or acquire an alternative clinical course, independent of the GI tract disorder. The 
systems mainly affected are the musculoskeletal system, skin, eyes, lungs and 
the hepatobiliary (HB) system (1). IBD-associated HB disorders typically include 
primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), and less 
frequently, primary biliary cirrhosis (PBC), cholangiocarcinoma, nonalcoholic fatty 
liver disease, hepatic abscess, and hepatic vascular abnormalities (2). The 
activity of HB disorders is usually independent of the bowel disease and does not 
parallel with it. Indeed PSC, the HB disorder most frequently found in association 
with IBD, can develop many years after colectomy, and IBD can appear in 
patients who have undergone liver transplantation for PSC (3). Concomitant IBD 
and PSC (IBD/PSC) are also characterized by different clinical manifestations 
with respect to IBD alone, suggesting that IBD/PSC may constitute a unique form 
of IBD (4).  
Etiology of IBD-associated liver disorders 
The etiology of IBD-associated HB disorders still remains unclear. AIH is 
commonly regarded as an autoimmune disease and shows typical features such 
as female predilection, presence of disease-specific autoantibodies, and 
responsiveness to immunosuppressive medications (5). PSC, instead, does not 
completely fit into the autoimmune classification and two models are classically 
implicated in its etiology: atypical autoimmunity and immune-mediated 
inflammation (6). Both IBD and its extra-intestinal manifestations are 
characterized by extensive infiltration of inflammatory cells, particularly 
lymphocytes, regardless of their localization. For example, in PSC, a massive 
inflammatory infiltrate is observed in hepatic portal tracts and areas of piecemeal 
necrosis that consists predominantly of T cells (7).  
Currently, the most widely-accepted hypothesis of IBD-associated liver disease, 
particularly PSC, is that it occurs as a consequence of aberrant adhesion 
molecule expression that promotes recruitment of memory T-cells, originally 
activated in the gut, to the liver where they drive hepatic inflammation (8). 
Specifically, expression of mucosal addressin cell adhesion molecule-1 
(MAdCAM-1) and the chemokine CCL25 are normally restricted to the intestinal 
endothelium and small bowel epithelium, respectively, and comprise the 
conventional gut “postal code (9)”. In PSC, MAdCAM-1 and CCL25 are 
aberrantly found on portal and sinusoidal endothelium, suggesting the 
importance of these homing molecules for the migration of T-cells to the liver (10, 
11). Together, these observations support the existence of an enterohepatic 
lymphocyte circulation that facilitates trafficking of T-lymphocytes from the gut to 
the liver that can promote liver inflammation. 
Alternatively, emerging evidence suggests that T-lymphocyte priming can also 
occur in the liver during both homeostatic and pathologic conditions (12-14).  
Liver-resident antigen presenting cells (APC), such as LSEC, dendritic cells 
(DC), and Kupffer cells (KC), are capable of interacting with naïve T-cells and 
have the ability to induce regulatory T-cells (Treg) differentiation and function (15, 
16). In particular, LSEC can induce both Forkhead Box Protein 3 (FoxP3) 
positive and negative Treg, but can also suppress CD4 and CD8 effector T-cells 
(14, 17-19), and are considered to be crucial for promoting T-cell tolerance within 
the hepatic environment. 
The SAMP1/YitFc mouse model 
Of the many available murine models of IBD, only few allow investigation of the 
earliest events associated with the onset and progression of disease. 
SAMP1/YitFc mice (SAMP) represent a well-characterized model of 
spontaneous, chronic intestinal inflammation, whose primary disease location 
(i.e., terminal ileum), histologic features, and response to therapy closely 
resemble CD, one of the idiopathic forms of IBD (20, 21). This mouse strain was 
derived from brother-sister breeding of wild type AKR mice and the phenotype 
develops spontaneously without chemical, genetic or immunological manipulation 
by 10 weeks of age (22). Previous unpublished findings by our group reported a 
liver phenotype occurring prior to the onset of intestinal inflammation in SAMP. 
Indeed, abundant inflammatory infiltrates were detected as early as 1-week in 
SAMP compared to healthy AKR controls, when no histologic evidence of ileitis is 
typically present (20-22). The peak of liver inflammation occurred at 4-weeks in 
SAMP, when ileitis is not yet detected histologically, and gradually diminished 
over time, most significantly in areas of lobular compared to portal involvement. 
Therefore liver inflammation displays an opposite tendency with respect to the 
ileitis, which progressively increases in severity, reaching maximum inflammation 
by 20-weeks. Accordingly, the SAMP model is ideal to evaluate the onset and 
progression of liver inflammation in the presence of chronic ileitis, and to 
investigate the relationship and potential mechanism(s) linking gut and liver 
pathologies. 
 
  
Aim of the study 
The presence of inflammatory infiltrates in hepatic portal tracts was previously 
reported in 20- to 30-week-old SAMP (21, 23); however, this observation was not 
further characterized. Indeed, the cellular mechanism(s) responsible for the liver 
phenotype observed in ileitis-prone SAMP is unknown. Interestingly, adoptive 
transfer of CD4+ T-cells derived from SAMP gut-associated lymphoid tissue 
(GALT) into naïve SCID recipients results in ileitis (20), supporting a key role of 
CD4+ T-cells in the pathogenesis of SAMP ileitis. Of note, inflammatory cells 
infiltrating portal tracts of PSC patients consist predominantly of T-cells, highly 
producing TNF (7, 24). Taken together, these findings suggest that T-cells, 
particularly CD4+ T-cells, may be important not only in IBD, but also in its extra-
intestinal manifestations, such as hepatic inflammation. 
The aim of the present study is to characterize the role played by the immune 
compartment, particularly liver-resident CD4+ T-cells, in SAMP hepatic 
inflammation. Herein, we hypothesize that intrahepatic CD4+ T-cells undergo 
pathogenic activation and drive inflammation in the SAMP liver, as a 
consequence of impaired immunosuppression mediated by Treg.  
The specific aims of this study are to: 
a) Investigate the relative contribution of host intrinsic factors, i.e. the 
epithelial permeability defect characterizing SAMP, and the hematopoietic 
compartment in SAMP hepatic inflammation by generating bone marrow 
chimeric mice and SAMPxRAG-1 KO mice 
b) Test the activation phenotype and the pathogenic potential of liver- and 
GALT-derived CD4+ T-cells from SAMP and AKR controls by flow 
cytometry and by adoptively transferring CD4+ T-cells into naïve SCID 
recipient mice 
c) Measure the protein expression in SAMP liver of homing molecules 
usually restricted to the gut that are overexpressed in PSC patients, such 
as MAdCAM-1 and CCL25, and the frequency of CD4+ T-cells expressing 
their counterpart ligands, i.e., α4β7 and CCR9, by flow cytometry 
d) Evaluate the frequency of liver-resident tolerogenic populations, i.e., LSEC 
and Treg, in SAMP vs. AKR by flow cytometry  
e) Test the in vitro proliferation and suppression, respectively, of effector and 
regulatory CD4+ T-cells resident in SAMP and AKR liver. 
  
Materials and methods 
Mice 
Original AKR/J (AKR), B6.129S7-Rag1tm1Mom/J (RAG-1 knockout (KO)), and 
C3Smn.CB17-Prkdcscid/J (SCID) mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). SAMP founders were provided by S. Matsumoto 
(Yakult Central Institute for Microbiological Research, Tokyo, Japan) (20, 22). 
SAMPXRAG-1 KO were generated by backcrossing RAG-1 KO onto SAMP for 
10 generations. Experimental mice were maintained under specific pathogen-free 
conditions, fed standard laboratory chow (Harlan Teklad, Indianapolis, IN), and 
kept on 12h light/dark cycles. All procedures followed AALAC guidelines and 
were approved by CWRU’s IACUC. 
Histology and Immunohistochemistry 
Liver and ileal tissues were processed for histology (20, 23, 25-30) and evaluated 
by trained pathologists (T. Roskams, J. Mize) using a novel liver and established 
ileal (23, 26-32) scoring systems. Immunolocalization of T-cells and TNF was 
performed using α-CD3 (ab5690/1:50), and α-TNF (ab1793/1:20) primary 
antibodies (all from Abcam, Cambridge, MA), and visualized using the Dako 
EnVisionTM System (Dako, Carpinteria, CA). Images were obtained on an 
Axiophot microscope and assembled by Axiovision Release 4.5 (Carl Zeiss, Inc., 
Thornwood, NY). 
NPLC Isolation 
NPLC were isolated by perfusing mice with HBSS through the hepatic portal 
vein, after which livers were removed and homogenized. Homogenates were 
incubated with agitation at 37°C for 30 min in a solution of 0.05% collagenase 
type IV and DNase I, in HBSS (Sigma-Aldrich, St. Louis, MO). Resulting cell 
suspensions were centrifuged at 300 rpm at 4°C, passed through 40-mm nylon 
filters, and centrifuged again at 1200 rpm at 4°C for 10 min. ACK Lysing Buffer 
(Invitrogen, Carlsbad, CA) was added to cell pellets for 5 min at room 
temperature and similarly centrifuged. Cells were washed twice and used for 
immediate experimentation, or further purified by centrifugation at 2500 rpm for 
30 min through a 25%/50% Percoll gradient (Sigma-Aldrich), or enriched for 
CD4+ T-cells (described below). Cells were washed twice and then used for 
experiments. 
Flow Cytometry 
Single-cell suspensions were prepared from mesenteric lymph nodes (MLN) (28) 
and livers, and 106 cells stained with the following antibodies: PerCP-labeled 
CD4 (RM4-5), APC-labeled CD25 (PC61) (BD Pharmingen, San Diego, CA), 
APC-labeled α4β7 (PS/2) (AbD Serotec, UK), PE-labeled CCR9 (242503) (R&D 
System, Minneapolis, MN), APC-labeled CD146 (ME-9F1), APC-Cy7-labeled 
CD11c (N418), PE-labeled I-Ak (10-3.6), CD69 (H1.2F3), Brilliant Violet 421-
labeled CD62L (MEL-14) (Biolegend, San Diego, CA), and eFluor®450-labeled 
F4/80 (BM8) (eBioscience, San Diego, CA). For intracellular staining, cells were 
fixed after cell-surface staining, followed by permeabilization and staining with 
PE-labeled FoxP3 (FJK-16s) (eBioscience). Samples were analyzed with a BD 
FACS Calibur and CellQuest Software (Becton Dickinson, San Jose, CA). 
Adoptive Transfer Model 
Livers and MLN were harvested from 10- to 12-week-old donors, rendered into 
single cell suspensions, and purified for CD4+ lymphocytes using magnetic bead 
separation (MACS, Miltenyi Biotec, Auburn, CA).  CD4+ T-cells (400,000) were 
transferred intraperitoneally into 6- to 8-week-old major histocompatibility 
complex (MHC)-matched SCIDs; untransferred SCIDs receiving PBS (vehicle) 
served as controls.  Six-weeks post-transfer, recipient mice were euthanized and 
liver and ilea processed for histological evaluation and intrahepatic CD4+ T-cell 
isolation, again using MACS (Miltenyi Biotec). 
Cytokine mRNA Expression 
NPLC and ex vivo-cultured α-CD3/CD28-activated CD4+ T-cells (32) were lysed 
in Buffer RLT (Qiagen, Germantown, MD) immediately after collection. Total RNA 
was isolated using RNeasy Mini Kits (Qiagen) and reverse-transcribed to cDNA 
(RNA-to-cDNA kit, Applied Biosystems, Forest City, CA). Real-time qPCR was 
performed using the following primers: interferon (IFN-γ) (5’-
GCCAAGTTTGAGGTCAACAAC-3’; 5’-CCGAATCAGCAGCGACTC-3’), tumor 
necrosis factor (TNF) (5’-GCGGTGCCTATGTCTCAG-3’; 5’-
GCCATTTGGGAACTTCTCATC-3’), interleukin (IL)-10 (5’-
TTTAAGGGTTACTTGGGTTGC-3’; 5’-CCGCATCCTGAGGGTCTTC-3’), IL-4 (5’-
GCTAGTTGTCATCCTGCTCTTC-3’; 5’-GGCGTCCCTTCTCCTGTG-3’), IL-5 (5’-
GCTTCTGCACTTGAGTGTTCTG-3’; 5’-CCTCATCGTCTCATTGCTTGTC-3’), IL-
13 (5’-TTGCTTGCCTTGGTGGTCTC-3’; 5’-GGGAGTCTGGTCTTGTGTGATG-
3’), and β-actin (5’-CAGGGTGTGATGGGAATG-3’, 5’- 
GTAGAAGGTGTGGTGCCAGAT-3’). RT-PCRs were performed using an 
Applied Biosystems Step Plus machine (Applied Biosystems). Reaction mixture 
consisted of 15% volume first-strand synthesis in a total volume of 20 µl that 
included Power SYBR Green reagents (Applied Biosystems) and 500 nM final 
concentrations of primers. Thermal cycling conditions were 95°C/10 min followed 
by 40 cycles of 95°C/15 sec and 60°C/1 min. Expression of all the genes of 
interest was normalized to β-actin. 
Bone marrow chimeras 
Reciprocal bone marrow chimeras (BMC) were generated as previously 
described (26), with minor modifications. Briefly, bone marrow (BM) was 
harvested from femurs and tibias of 4-week-old SAMP and AKR. Cell 
suspensions were washed and diluted to a concentration of 37.5 × 106 cells/ml in 
HBSS. 7.5 × 106 cells/200 µl were injected intravenously into the lateral tail veins 
of irradiated 10-week-old recipients. Mice were placed on antibiotic water for 2-
weeks after irradiation, then on autoclaved water for 6-weeks, after which they 
were euthanized, and livers and ilea collected. 
MAdCAM-1 and CCL25 Protein Levels 
Livers were collected and homogenized in RIPA buffer supplemented with Halt 
proteases and phosphate inhibitor cocktail (Pierce Biotechnology, Rockford, IL), 
using Lysing Matrix tubes and FastPrep®-24 (MP Biomedicals, Santa Ana, CA). 
Homogenates were centrifuged at 12,000 rpm, supernatants collected, and total 
protein content measured using BCA Protein Assay Kits (Pierce Biotechnology). 
After normalizing protein content, tissue homogenates were assayed for 
MAdCAM-1 and CCL25 protein by ELISA (R&D System). 
In vitro T-cells proliferation and suppression assay  
Fluorescence-activated cell sorting (FACS)-purified CD4+ CD25- effector T-cells 
(Teff) and CD4+ CD25+ Treg were isolated from 10-weeks-old mice. Teff were 
labeled with eFluor 670 (CFSE analog, 0.5 µM) and cultured with or without a 1:1 
ratio of Treg. α-CD3 (1 µg/ml-1) and α-CD28 (1 µg/ml-1)-coated beads (Miltenyi 
Biotec) were added to cultures at 1:1 bead:Teff ratio. Proliferation was 
determined after 3 days of culture by flow cytometric dye dilution assay. 
 
Statistical Analysis 
Two-tailed unpaired Student’s t-test with Welch’s correction and one-way 
ANOVA using Bonferroni’s correction were performed using GraphPad Prism 5 
(GraphPad Software, Inc., La Jolla, CA). Results are expressed as mean ± SEM; 
p-values < 0.05 were considered significant. 
Results 
SAMP display immune-mediated liver inflammation  
The main histopathologic features in SAMP liver consisted of portal tract 
inflammation characterized by T-cell infiltrates, eosinophilic polymorphonuclear 
lymphocytes, and macrophages, as well as focal hepatitis with T-cells infiltrating 
the portal-parenchymal interface (Figure 1A) with inflammatory bridging between 
portal tracts (Figure 1B).  
Figure 1.  Liver inflammation in SAMP resembles liver involvement in IBD patients.  (A) Main, pathologic 
features of SAMP liver include infiltration of the portal-parenchymal interface with occasional inflammatory bridging 
(arrows) between portal tracts (B), (C) focal CD3+ T-cell infiltration (arrows) of bile duct (BD) epithelium, with TNF-
expressing macrophages (arrows, D), and (E) hepatocyte anisokaryosis with inflammatory infiltration of liver lobules, 
often in the form of granulomas (F); in a limited number of SAMP, mild microvescicular steatosis occurs in 
association with sinusoidal inflammation (G).  Bars: (A, B, F) 50µm, (C, D, G) 20µm, and (E) 100µm.   
 Remarkably, the bile duct epithelium was focally infiltrated by CD3+ T-
lymphocytes (Figure 1C), with TNF-expressing cells morphologically consistent 
with macrophages also detected in portal tracts and sinusoids (Figure 1D). In 
addition to prominent portal tract involvement, other pathologic features 
recapitulated most of those described in IBD (33), such as hepatocyte 
anisokaryosis (Figure 1E), granuloma-like organization of lobular inflammatory 
infiltrates (Figure 1F), and sinusoidal inflammation with mild microvescicular 
steatosis (Figure 1G). Overall, the general histopathologic findings were 
indicative of immune-mediated liver disease, involving both portal tracts and liver 
lobules, with infiltration of biliary ducts, reminiscent of the clinical phenotype of 
PSC/AIH overlap syndrome. 
SAMP hematopoietic cells induce liver inflammation independently of host-
intrinsic factors 
To determine whether SAMP liver inflammation, similarly to ileitis, originates from 
a non-hematopoietic source (26), reciprocal BMC were generated by 
reconstituting irradiated SAMP with AKR BM (AKR→SAMP) and irradiated AKR 
with SAMP BM (SAMP→AKR). The severity of liver and ileal inflammation was 
assessed 8 weeks post-transplant. As previously reported (26), SAMP→AKR 
BMC showed no ileal inflammation (similar to AKR→AKR controls), whereas 
AKR→SAMP displayed inflammatory scores comparable to SAMP→SAMP BMC 
(Figure 2A). Conversely, liver inflammation was detected in both reciprocal BMC 
(SAMP→AKR and AKR→SAMP), as well as in SAMP→SAMP (Figure 2B). 
Histologically, liver inflammation in AKR→SAMP, SAMP→AKR and 
SAMP→SAMP was similar to that observed in native SAMP and was 
characterized by infiltration of inflammatory cells, particularly abundant in 
enlarged portal tracts, with minor involvement of liver lobules (Figure 3). 
Figure 2.  Hematopoietic-derived cells are required to induce SAMP liver inflammation.  Liver (A) and ileal 
(B) diseases severity SAMP/AKR BMC (n=9-12 per group):  SAMP→AKR, AKR→SAMP, SAMP→SAMP, and 
AKR→AKR BMC. *p<0.05, **p<0.01, ***p<0.001 vs. AKR→AKR. 
To investigate the role played by lymphocytes within the hematopoietic 
compartment, SAMPXRAG-1 KO mice were generated by backcrossing RAG-1-
deficient mice (34) onto the SAMP background in order to produce SAMP lacking 
mature T- and B-lymphocytes. SAMPXRAG-1 KO mice developed only mild, if 
any, liver inflammation compared to SAMPXRAG-1 wild-type (WT) littermates 
(Figure 4).  
Figure 3.  Hematopoietic-derived cells are required to induce SAMP liver inflammation.  Representative 
histologic photomicrographs of SAMP/AKR BMC liver (n=9-12 per group). Bars: 70µm. 
 Interestingly, cytokine gene expression measured during peak liver inflammation 
in SAMP (4 weeks of age) showed increased IL-1β, IFNγ, and TNF mRNA 
transcript levels and decreased IL-4, IL-13 and IL-10, compared to age-matched 
AKR (Figure 5), indicating that the cytokine milieu during peak hepatic 
inflammation is skewed towards a proinflammatory/Th1 profile.  
Figure 4.  Liver inflammation is abrogated in the absence of mature 
lymphocytes in SAMP. Severity of liver inflammation in SAMPXRAG-1 
KO vs. WT mice (n=7-14 per group). ***p<0.001 vs. SAMPxRAG-1 WT. 
Previous findings from our group highlighted a marked increase of CD3+ T-cells, 
specifically of CD4+ T-cells, as early as 4 weeks of age, while no difference in the 
percentages of CD8+ T-cells was observed between SAMP and AKR livers 
(unpublished data). Moreover, CD4+ T-cell expressed CD69, CD44hi and CD62L 
at higher percentages in SAMP vs. AKR liver (unpublished data), indicating an 
increased pool of activated effector and naïve liver T-cells that retain the ability to 
recirculate through lymph nodes. 
Figure 5.  Non-parenchymal liver cells overproduce Th1-like cytokines in inflamed SAMP liver. Relative mRNA 
expression of hepatic proinflammatory, Th1, and Th2 cytokines in NPLC from 4 weeks old mice (n=8). *p<0.05, 
**p<0.01 vs. AKR. 
SAMP intrahepatic CD4+ T-cells transfer both liver and ileal inflammation 
into SCID recipient mice 
Interestingly, at 10-12 weeks, when both ileal and liver inflammation are 
established, a distinct population of CD4+CD62L+CD69+ T-cells was identified in 
SAMP MLN that was substantially diminished in the liver (Figure 6).  
 
 
These cells likely represent a pathogenic population comprised of naïve T-cells 
that have homed to the MLN and are undergoing activation after exposure to a 
Th1-polarizing environment. Indeed, GALT-derived CD4+ T-cells from SAMP 
have been shown to induce ileitis when adoptively transferred into 
immunodeficient recipients (20, 27, 29, 35). Contrary to that previously reported 
Figure 6.  Phenotypic activation of MLN- and liver-derived CD4+ T-cells. Percentages of activated CD4+ T-cell 
subsets (left) and representative flow cytometry analysis (right) in 10-12-wk-old mice (n=3-5). **p<0.01, ***p<0.001, 
‡p<.01 vs. AKR. 
in   4 weeks old livers, the percentages of CD4+CD69+ T-cells were not increased 
in older (10-12 weeks) SAMP vs. AKR (Figure 6), confirming that SAMP liver 
attains an active state of inflammation early, and sustains severe disease until 10 
weeks, when inflammation begins to diminish. 
We next determined whether CD4+ effector T-cells derived from SAMP liver had 
the ability to transfer either liver and/or ileal disease. Liver inflammation 
developed following adoptive transfer of liver-derived CD4+ T-cells from SAMP 
(Figure 7), while MLN-derived cells were not able to induce significant liver 
inflammation vs. AKR donor T-cells (Figure 8).  
 
Figure 7.  Liver-derived SAMP CD4+ T-
cells are uniquely able to induce 
hepatic inflammation in SCID 
recipients. Liver inflammation in 
recipient mice following adoptive transfer 
of donor CD4+ T-cells derived from liver 
or MLN of donor mice; recipients 
receiving vehicle only served as controls 
(Ctrl) (n=8-10). *p<0.05 vs. AKR donors. 
 Similar to native SAMP (Figure 5), intrahepatic CD4+ T-cells from SCIDs 
receiving SAMP liver cells expressed higher levels of TNF and IFNγ mRNA 
transcripts compared to those receiving MLN T-cells (Figure 9).  
 
Importantly, prominent ileitis developed in recipient mice following transfer of 
liver-derived SAMP CD4+ T-cells that was more severe than observed after 
transfer of MLN-derived cells, as well as control (untransferred) recipients, which 
displayed no histologic signs of inflammation (Figure 8 and 10).  
Figure 8.  Intrahepatic SAMP CD4+ T-cells can 
transfer both hepatic and ileal inflammation 
whereas MLN-derived CD4+ T-cells transfer only 
ileitis. Ileitis severity in SCID mice receiving SAMP 
CD4+ T-cells derived from MLN or liver of donor 
mice. *p<0.05, **p<0.01, ***p<0.001. 
Figure 9.  Intrahepatic CD4+ T-cells from SCID receiving SAMP donor cells overexpress Th1 cytokines. 
Th1/Th2 cytokine mRNA expression in activated ex vivo-cultured intrahepatic CD4+ T-cells from recipients of donor 
SAMP liver vs. MLN cells (N=4 per group). *p<0.05, **p<0.01  
Together, these data suggest that liver-derived effector CD4+ T-cells have the 
ability to drive both liver and ileal inflammation in native SAMP, while those 
derived from GALT (i.e., MLN) can only produce ileitis. 
Gut-specific homing molecules are unchanged in SAMP liver 
According to the most commonly-accepted hypothesis, IBD-associated liver 
inflammation is the result of lymphocyte homing, specifically of α4β7+ and/or 
CCR9+ cells that are originally activated in the gut and are subsequently recruited 
to the liver (8). Interestingly, the percentages of CD4+ T-cells positive or highly-
expressing the homing receptors, α4β7 and CCR9, were unchanged in SAMP vs. 
AKR livers during peak inflammation (Figure 11).  
 
 
Figure 10. Liver-derived SAMP CD4+ T-cells induce more severe ileitis respect to MLN-derived SAMP CD4+ T-
cells. Representative histologic photomicrographs displaying epithelial crypt hypertrophy and elongation, and villous 
blunting with dense inflammatory infiltrates throughout mucosa and submucosa in recipients of liver-derived donor 
cells (left), which was less severe in ilea adoptively transferred with MLN-derived donor cells (middle) and Ctrl (right).  
Bars: 50µm.   
 Consistently, protein levels of MAdCAM-1 and CCL25, cognate ligands for α4β7 
and CCR9, were also similar in SAMP vs. AKR livers at 4 weeks, and decreased 
or did not change, respectively, at 20 weeks (Figure 12).  
 
Figure 11. CD4+ T-cells do not overexpress α4β7+ 
and CCR9+ in SAMP liver.  (A) Percentages of 
intrahepatic CD4+ T-cell subsets from 4 weeks old 
mice. Isolated NPLC were first gated on CD4 and 
successively on α4β7 and CCR9, distinguishing 
between overall positive cells and highly expressing 
cells (n=5).  
 
Figure 12. MAdCAM-1 and CCL25 
expression is not increased in SAMP 
liver.  Protein concentration of MAdCAM-1 
(A) and CCL25 (B) measured by ELISA in 
liver homogenates of 4 and 20 weeks old 
mice; *p<0.05. 
These data suggest that SAMP are not likely experiencing enhanced recruitment 
of gut-activated CD4+ T-cells to the liver. 
LSEC and Treg frequencies are altered in SAMP liver 
To test whether the pathogenic potential of SAMP liver effector CD4+ T-cells may 
be due to altered antigen presentation by liver-resident APC, the frequency of 
APC subsets and their expression of MHC class II I-Ak were measured.  
Surprisingly, no differences were observed in the frequency of either F4/80+ 
macrophages or CD11c+ DC between SAMP and AKR livers, while CD146+ 
LSEC were markedly decreased and displayed increased I-Ak expression in 
SAMP compared to AKR during peak liver inflammation (Figure 14 and 15).  
 
 
 
Figure 14. LSEC frequency is decreased in SAMP liver. 
Percentages of intrahepatic positive cells for F4/80, CD11c, 
CD146 in total cell gate; one observation (n) represents 
pooled samples from 2-3 mice/livers; (n=4-6); *p<0.05   
Figure 15. LSEC overexpress MHC class II I-Ak+ in SAMP 
liver. Percentages of intrahepatic positive cells for IAk in 
CD146 gate; one observation (n) represents pooled samples 
from 2-3 mice/livers; (n=4-6), **p<0.001. 
The reduced frequency of LSEC in SAMP also associated with a decreased 
percentage of hepatic FoxP3+ Treg (Figure 16).  
 
Together, these data suggest that LSEC-mediated induction of hepatic Treg may 
be impaired in SAMP, which can promote immunoregulatory dysfunction and 
local inflammation within the liver. 
In vitro immunosuppression by Treg is impaired in SAMP liver 
To investigate whether the immunosuppressive function of liver-resident Treg is 
altered in SAMP liver, we used the CFSE suppression assay to evaluate both the 
proliferation of effector CD4+ T-cells and the suppression of Treg. Effector CD4+ 
CD25- T-cells and CD4+ CD25+ Treg were isolated by FACS from SAMP and 
AKR livers according to the gating strategy showed in Figure 17.  
Figure 16. FoxP3+ Treg frequency is decreased in SAMP liver. (A) Percentages of intrahepatic 
FoxP3+ cells calculated within CD4 gate, with (B) representative plots (n=3), *p<0.05. 
 Effector T-cells were labeled with eFluor 670 (CFSE analog) and cultured with α-
CD3/CD28, with or without Treg for 3 days. We found that the percentage of 
dividing cells (reduced CFSE) stimulated with α-CD3/CD28 was higher in SAMP 
compared to AKR cultures (87.1% vs. 77.4%, respectively) (Figure 18), 
suggesting that effector CD4+ T-cells over-proliferate in SAMP inflamed liver 
compared to AKR controls.  
 
Figure 17. FACS sorting scheme for isolation of CD4+CD25+ and CD4+CD25- cells. CD4+CD25+ and CD4+CD25- 
cells were isolated from SAMP and AKR mice by FACS. Figure shows sequential gating on lymphocytes by FSC-A 
and SSC-A, followed by exclusion of aggregates by SSC-W and SSC-A. Singlet lymphocytes were selected on CD4 
positive fluorescence and then CD25 positive and negative expression. 
Figure 18. Effector CD4+ T-cells display increased proliferation in vitro in SAMP liver. CD4+ CD25- cells 
(Teff) were isolated from 10-week-old SAMP and AKR mice by FACS, labeled with eFluor670 dye and 
cultured in vitro in the presence or absence of α-CD3/CD28 for 3 days. Histograms show the proliferation of 
viable, CD4-gated cells in the absence (gray peaks) and presence (white peaks) of α-CD3/CD28. Percentages 
are referred to dividing cells in the presence of α-CD3/CD28 (n=15 pooled mice per group). 
Suppression by Treg is expressed as the percentage of proliferating cells (eFluor 
670 ‘‘low’’) inhibited by co-culture with Tregs, and was calculated by normalizing 
the difference of proliferating cells with and without Treg to the proliferation in the 
absence of Treg. Interestingly, liver-resident Treg from SAMP were less effective 
at suppressing the proliferation of hepatic effector CD4+ T-cells than Treg from 
AKR (5.3% vs. 18.3%, respectively) (Figure 19).  
 
 
 
 
 
These data demonstrate that liver-resident Treg from SAMP are dysfunctional in 
vitro and unable to suppress the proliferation of hepatic effector CD4+ T-cells as 
effectively as Treg from AKR control.  
Figure 19. Treg are dysfunctional in vitro in SAMP liver. CD4+ CD25- (Teff) and CD4+ CD25+ (Treg) 
cells were isolated from 10-week-old SAMP and AKR mice by FACS. Teff were labeled with eFluor670 
dye and cultured in vitro in the presence of α-CD3/CD28 with or without Treg for 3 days. Histograms 
show the proliferation of viable, CD4-gated cells in the absence (gray peaks) and presence (white peaks) 
of Treg (B). Percentages are referred to Treg suppression (n=15 pooled mice per group).  
 
Discussion 
Although liver disease has previously been reported in ileitis-prone SAMP mice 
(22, 23), the precise histologic features, onset and progression of disease, 
pathogenic mechanism(s), as well as its translational implications to IBD, have 
not been fully addressed. Interestingly, evaluation of SAMP livers suggests a 
clinical phenotype resembling PSC/AIH overlap syndrome, which can also 
represent a comorbidity with IBD (33). PSC/AIH overlap syndrome is defined as 
an immune-mediated disorder with cholangiographic findings, and histologic, 
biologic and/or clinical features of AIH. Histologic characteristics of AIH include 
piecemeal necrosis, lymphocyte rosetting, and moderate to severe periportal or 
periseptal inflammation (36), which are features also found in SAMP livers. 
Although liver involvement in IBD is commonly regarded as a consequential 
secondary event to gut inflammation, peak hepatic inflammation occurs in SAMP 
as early as 4 weeks of age, prior to the onset of ileitis. This finding suggests that 
in SAMP, the presence of an inflamed gut is not required to trigger hepatic 
inflammation and that other mechanism(s), intrinsic to the liver or host, may 
induce liver disease. It could also be postulated that the inherent epithelial barrier 
defect present in SAMP ileum (26) facilitates translocation of luminal antigens 
into the immune-tolerant gut, and subsequently into the liver, increasing local 
antigen encounter. In this scenario, the liver could be prone to early challenge 
and generate a vigorous inflammatory response induced by mechanism(s) 
involving the loss of hepatic tolerance. However, we show that SAMP 
hematopoietic cells are uniquely able to induce liver, but not ileal, inflammation in 
AKR recipients independently of SAMP-inherent factors, such as the ileal 
permeability defect. Therefore, unlike ileitis in SAMP mice, the ‘leaky gut’ may 
facilitate, but does not appear to be the primary mechanism leading to, liver 
disease. Additional defects in the immune compartment are likely required to 
induce the hepatic phenotype. Nonetheless, irradiated SAMP receiving AKR BM 
also displayed hepatic inflammation, even in the presence of a healthy immune 
compartment, a finding that may be due to pathogenic interaction(s) of healthy 
AKR immune cells with the diseased SAMP host, which survive irradiation. 
Aberrantly activated AKR immune cells can then enter the enterohepatic 
circulation and contribute to both organ phenotypes. In fact, gut- and liver-
activated lymphocytes have been shown to migrate to the liver and gut, 
respectively, particularly CD8+ T-cells in the former, and CD4+ T-cells in the 
latter, case (37, 38). 
The concept of a pivotal role for the immune compartment, particularly 
lymphocytes, during SAMP liver inflammation is further supported by the hepatic 
phenotype observed in SAMPXRAG-1 KO mice, wherein the absence of mature 
lymphocytes is sufficient to abrogate liver disease, even in the presence of a 
compromised intestinal barrier. Functional lymphocytes are therefore necessary 
for the development of SAMP liver disease, and similar to the early inductive 
phase of ileitis wherein Th1 cytokines predominate (20), the SAMP hepatic 
environment is also Th1-skewed and enriched for CD4+ T-cells. This Th1 milieu 
is already established at 4 weeks, before ileitis, and suggests the presence of a 
shared pathogenic mechanism between the two organs that is able to induce 
similar phenotypes and immune responses, albeit temporally separated. 
Interestingly, SAMP-derived intrahepatic CD4+ T-cells display an activated 
phenotype and are able to adoptively transfer both liver and ileal inflammation, 
while GALT-derived CD4+ T-cells transfer ileitis only. Therefore the liver, rather 
than the gut, provides a pool of pathogenic Th1 CD4+ T-cells able to induce 
hepatic inflammation. This contrasts with the widely accepted hypothesis that 
IBD-associated liver inflammation is mediated by long-lived, GALT-derived a4b7+ 
and CCR9+ T-lymphocytes later recruited to the liver (11, 39, 40). Unlike the ileal 
phenotype (23, 30, 31, 41), we were unable to detect any significant differences 
in intrahepatic a4b7+ and CCR9+ CD4+ T-cell frequencies or their corresponding 
ligands, MAdCAM-1 and CCL25, respectively, in SAMP compared to AKR livers. 
This provides further strength for the hypothesis that host hepatic defects, rather 
than aberrant recruitment of gut-activated lymphocytes, are responsible for the 
ileitis-associated liver phenotype observed in SAMP mice. Recently, LSEC have 
been reported to induce expression of a4b7 and CCR9 in naïve CD4+ 
lymphocytes (38), challenging the concept that lymphocytes expressing these 
molecules are exclusively gut-derived, and suggests instead that priming of gut 
tropic CD4+ T-cells may also occur in the liver. This implies that aberrant 
expression of MAdCAM-1 and CCL25 reported in PSC patients (10, 11), may not 
be the only cause of increased intrahepatic lymphocyte frequency observed in 
IBD-associated liver inflammation. 
Effector functions of intrahepatic T-lymphocytes depend both on their site of 
primary activation and on the type of T-cells considered, particularly whether 
these are CD4+ or CD8+ T-lymphocytes (12, 42). Increasing evidence suggests 
that antigen presentation in the liver mainly results in activation of CD8+ T-cells, 
whereas the effect on CD4+ lymphocytes is still controversial (13, 14, 43). 
Despite the pro-inflammatory environment characteristic of the SAMP liver during 
peak inflammation, we could not detect significant differences in DC and KC 
frequencies and their MHC class II expression between SAMP and AKR. 
Therefore, increased antigen presentation by traditional liver-resident APC is 
unlikely to be the main mechanism by which CD4+ T-cells acquire pathogenic 
potential in the inflamed SAMP liver. Typically, antigen presentation by LSEC to 
CD4+ T-cells does not result in an effective immune response, but rather leads to 
the induction of hepatic tolerance (14, 43). LSEC-mediated tolerance can be 
conferred to CD4+ T-cells by several mechanisms, and relevant to this study, by 
induction of CD4+ FoxP3+ Treg, but also by direct inhibition of Th1 effector CD4+ 
cells (17, 18). LSEC normally express low levels of MHC class II as a 
consequence of exposure to IL-10, abundant in the homeostatic liver, which 
determines a shift from an activated to inhibitory phenotype with the ability to 
suppress IFN-γ secretion from CD4+ T-cells (17, 44). LSEC are not only 
decreased in frequency in inflamed SAMP liver, but also display greater 
expression of MHC class II, consistent with diminished IL-10 mRNA expression 
observed in SAMP NPLC. As such, downregulation of IL-10 in inflamed SAMP 
liver likely determines a shift in LSEC phenotype and function, impairing their 
ability to effectively suppress effector CD4+ T-cells. Along with reduced LSEC, 
we observed diminished FoxP3+ Treg in SAMP liver, which suggests that the 
decreased frequency of LSEC and of anti-inflammatory signals may deter the 
generation of homeostatic hepatic FoxP3+ Treg. Accordingly, it is possible that 
liver inflammation in SAMP mice does not originate from an inciting intestinal 
event, but from (an) inherent host defect(s). Indeed, GALT-derived SAMP Treg 
are unable to suppress in vivo effector CD4+ T-cell proliferation and display a 
pro-inflammatory phenotype (45). In this scenario, the reduced frequency and 
suppressive capacity of hepatic Treg would allow the uncontrolled proliferation of 
pathogenic Th1-activated intrahepatic CD4+ T-cells and drive liver inflammation 
in SAMP. Given the ability of intrahepatic CD4+ T-cells to also transfer ileal 
inflammation into immunodeficient recipient mice, it is likely that their 
uncontrolled proliferation may also contribute to SAMP ileitis. 
  
Conclusions 
In the present study, we identify one of the possible mechanisms contributing to 
IBD-associated liver disease in the ileitis-prone SAMP model and raise the 
possibility that hepatic involvement is more than a mere extra-intestinal 
manifestation of IBD. Overall, these results support a pathogenic role of 
intrahepatic CD4+ T-cells in both SAMP liver and intestinal inflammation, and 
suggest that impaired hepatic regulatory pathways may be responsible for their 
acquired pathogenicity and function. Moreover, these findings suggest that liver 
and intestinal inflammation in IBD, or at least in a subset of patients, may 
develop as concomitant disease processes, based on common host-driven 
immune defects. 
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